Clinical trial
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure…
NCT00104416 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00104416 |
|---|---|
| Title | Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures |
| Official title | A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy, Tonic-Clonic |
| Intervention type | Drug |
| Interventions | lamotrigine (LAMICTAL) extended-release, Placebo |
| Enrollment | 153 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 1, 2005 |
| Last update posted | Jan 2, 2017 |
| Countries | Argentina, Brazil, Chile, Germany, India, Malaysia, Puerto Rico, Russia, South Korea, Ukraine, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: